4D Molecular Therapeutics, Inc. (FDMT)

NMS – Цена в реальном времени. Валюта: USD

10.36

+0.02 (0.19%)

Рынок открыт: May 13, 2026, 10:01 AM EDT

08.05.2026

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to a loss of $0.86 per share a year ago.

07.05.2026

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2026 financial results, provided operational highlights and outlined expected upcoming milestones. 

04.05.2026

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in May.

17.04.2026

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 14, 2026, the compensation committee of the Company's board of directors granted five new non-executive employees 67,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

18.03.2026

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of a loss of $0.53 per share. This compares to a loss of $0.9 per share a year ago.

18.03.2026

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2025 financial results, provided operational highlights and outlined expected upcoming milestones.

16.03.2026

4DMT to Participate in Upcoming Investor Meetings

EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in March.

Видео

No Data

There is no data to display

Пресс-релизы

07.05.2026

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

17.04.2026

4DMT Announces New Employment Inducement Grants

18.03.2026

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

16.03.2026

4D Molecular Therapeutics, Inc. (FDMT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Meetings

Видео

No Data

Пресс-релизы

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Announces New Employment Inducement Grants

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Meetings

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Meetings

Видео

No Data

Пресс-релизы

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Announces New Employment Inducement Grants

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Meetings

Search stocks

4D Molecular Therapeutics, Inc. (FDMT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Meetings

Видео

No Data

Пресс-релизы

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Announces New Employment Inducement Grants

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Meetings

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Meetings

Видео

No Data

Пресс-релизы

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Announces New Employment Inducement Grants

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Meetings